Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
The development of solo therapies to treat both aspects of gliomas promises to yield more-effective treatment with fewer risks of toxicity and drug interactions
CagriSema has been submitted for FDA review, but submitted is not the same thing as approved or available by prescription
Some doctors prescribe them off-label to manage alcohol use disorder, which the drugs appear to help for some people
Approval Timeline The developer of retatrutide is expected to file for FDA review by the end of the year, following the completion of phase 3 trials
JAMA 331 , 15191521 (2024)
US$ 28.75
US$ 21.17
US$ 23.10
